DBV Technologies and Centre d’Immunologie de MarseilleLuminy (CIML) enter in a Collaboration Agreement
The CIML is recognized for its advances in the knowledge of immune system cells involved in allergic reactions, a key stage in understanding the specific immunotherapy method using Viaskin® invented by DBV Technologies
BAGNEUX, FRANCE, October 16th 2012 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, announced today a partnership with Dr. Bernard Malissen who is working at the Centre d’Immunologie de Marseille-Luminy (CIML). His team is studying immune cells involved in allergic reactions (lymphocytes T and dendritic cells study). DBV Technologies and CIML have decided to collaborate to improve their knowledge of recruitment and mechanisms of actions involved in the epicutaneous treatment of allergies by the EPIT® (Epicutaneous Immunotherapy) method.